These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 10917541)

  • 1. United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) Strategy Group Workshop--'Clinical endpoints in trials of biological agents'.
    Br J Cancer; 2000 Aug; 83(3):294-7. PubMed ID: 10917541
    [No Abstract]   [Full Text] [Related]  

  • 2. United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) Strategy Group workshop. Improvements in patient access to new anti-cancer medicines.
    Br J Cancer; 1999 Jan; 79(1):2-3. PubMed ID: 10408683
    [No Abstract]   [Full Text] [Related]  

  • 3. The immunoregulatory function of polyphenols: implications in cancer immunity.
    de Carvalho JTG; Da Silva Baldivia D; de Castro DTH; Dos Santos HF; Dos Santos CM; Oliveira AS; Alfredo TM; Vilharva KN; de Picoli Souza K; Dos Santos EL
    J Nutr Biochem; 2020 Nov; 85():108428. PubMed ID: 32679443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination strategies for enhancing the efficacy of immunotherapy in cancer patients.
    Moschella F; Proietti E; Capone I; Belardelli F
    Ann N Y Acad Sci; 2010 Apr; 1194():169-78. PubMed ID: 20536466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular Targets in Cancer Therapy - Fourth Biennial Meeting. Mechanism and therapeutic reversal of immune suppression in cancer.
    Herber DL
    IDrugs; 2007 Apr; 10(4):227-9. PubMed ID: 17390239
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical trial designs for the early clinical development of therapeutic cancer vaccines.
    Simon RM; Steinberg SM; Hamilton M; Hildesheim A; Khleif S; Kwak LW; Mackall CL; Schlom J; Topalian SL; Berzofsky JA
    J Clin Oncol; 2001 Mar; 19(6):1848-54. PubMed ID: 11251017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ceplene encounters obstacles on the rocky road to FDA approval.
    Piascik P
    J Am Pharm Assoc (Wash); 2001; 41(2):346-7. PubMed ID: 11297343
    [No Abstract]   [Full Text] [Related]  

  • 8. Immunotherapeutic strategies for neoplasia.
    Talmadge JE
    Dev Biol Stand; 1992; 77():17-28. PubMed ID: 1426659
    [No Abstract]   [Full Text] [Related]  

  • 9. New wine in old bottles.
    Bennett B; Bennett L
    Cancer Biother Radiopharm; 2002 Jun; 17(3):249-53. PubMed ID: 12136517
    [No Abstract]   [Full Text] [Related]  

  • 10. The 11th Bristol-Myers Squibb Nagoya International Cancer Treatment Symposium. Cytokines and New Anticancer Agents on the Horizon of Oncology. Nagoya, Japan, 24-25 November 1995.
    Cancer Chemother Pharmacol; 1996; 38 Suppl():S1-119. PubMed ID: 8777775
    [No Abstract]   [Full Text] [Related]  

  • 11. Whatever happened to immunotoxins? Research, and hope, are still alive.
    Holzman DC
    J Natl Cancer Inst; 2009 May; 101(9):624-5. PubMed ID: 19401548
    [No Abstract]   [Full Text] [Related]  

  • 12. [Immunostimulating drugs and cytokines].
    Lehners N; Goldschmidt H; Raab MS
    Ther Umsch; 2011 Nov; 68(11):655-8. PubMed ID: 22045528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Upcoming innovations in lung cancer immunotherapy: focus on immune checkpoint inhibitors.
    Aspeslagh S; Marabelle A; Soria JC; Armand JP
    Chin Clin Oncol; 2015 Dec; 4(4):48. PubMed ID: 26730760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy in non-renal carcinomas.
    Keilholz U
    Urologe A; 2004 Sep; 43 Suppl 3():S138-40. PubMed ID: 15148577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Current status and future perspective of cancer immunotherapy--clinical application and development].
    Aruga A
    Nihon Geka Gakkai Zasshi; 2013 Nov; 114(6):327-31. PubMed ID: 24358730
    [No Abstract]   [Full Text] [Related]  

  • 16. Biological response modifiers used in cancer biotherapy.
    Kuroki M; Miyamoto S; Morisaki T; Yotsumoto F; Shirasu N; Taniguchi Y; Soma G
    Anticancer Res; 2012 Jun; 32(6):2229-33. PubMed ID: 22641656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant application of interferons.
    el Kassas H; Kirkwood JM
    Semin Oncol; 1996 Dec; 23(6):737-43. PubMed ID: 8970596
    [No Abstract]   [Full Text] [Related]  

  • 18. Biological response modifiers: current use and future prospects in cancer therapy.
    Bisht M; Bist SS; Dhasmana DC
    Indian J Cancer; 2010; 47(4):443-51. PubMed ID: 21131760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Innovations in the treatment of melanoma.
    Pavlick AC
    J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 3():S-34-7. PubMed ID: 23570097
    [No Abstract]   [Full Text] [Related]  

  • 20. Angiogenesis inhibitors in the treatment of prostate cancer.
    Adesunloye BA; Karzai FH; Dahut WL
    Chem Immunol Allergy; 2014; 99():197-215. PubMed ID: 24217611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.